We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Jeffrey S. Weber, MD, PhD
Ryan Sullivan, MD
Omid Hamid, MD
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Sapna Patel, MD
Jason J. Luke, MD, FACP
Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Lucio Manenti, MD, PhD
KALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Tara C. Mitchell, MD
Separating Fact from Fiction: The Realities of CKD-aP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD
Combining Biologics in a Young Patient with Atopic Dermatitis
Peter A. Lio, MD
Mark Boguniewicz, MD
Eric Simpson, MD, MCR
Using a Biologic in a Patient with Atopic Dermatitis and HSV Keratitis
Options for an Infant with Atopic Dermatitis
Advances in the Management of Moderate-to-Severe Atopic Dermatitis
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education